Stockscreener 앱 받기
21.59
9.98%
1.96
시장 영업 전:
21.99
0.40
+1.85%
Pulse Biosciences Inc 주식(PLSE)의 최신 뉴스
PLSE accelerates cardiac catheter program after breakthrough AFib data - MSN
Pulse Biosciences Shifts Focus to Catheter Electrophysiology Tech - Medical Product Outsourcing
How Pulse Biosciences’ nPulse AFib Refocus Will Impact Pulse Biosciences (PLSE) Investors - simplywall.st
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7%What's Next? - MarketBeat
PLSE Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Pulse Biosciences, Inc. 8-K SEC Filing March 23, 2026 – Company Information, NASDAQ Listing, and Key Details - Minichart
Pulse Biosciences Grants RSUs to Chief Technology Officer - TipRanks
Pulse Biosciences (NASDAQ: PLSE) awards CTO 100,000-share RSU grant - Stock Titan
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data - sharewise.com
PLSE Speeds Up Cardiac Catheter Initiative Following Landmark AFib Findings - Bitget
Stock Analysis: Is Pulse Biosciences Inc exposed to currency risks2026 Short Interest & Risk Managed Trade Strategies - baoquankhu1.vn
(PLSE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pulse Biosciences to accelerate Pulse Cardiac Catheter Ablation System - msn.com
Assessing Pulse Biosciences (PLSE) Valuation After The nPulse Cardiac Catheter Ablation Pivot - Sahm
Pulse Biosciences Touts 96% 12-Month Rhythm Control, Targets Q2 Start for U.S. AF IDE Study - Yahoo Finance
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
What's Going With Pulse Biosciences Stock On Monday? - MSN
Pulse Biosciences targets CE mark submission in 2026 as nPulse platform advances clinical milestones - MSN
Pulse Biosciences at Oppenheimer Conference: Promising AF Ablation Results By Investing.com - Investing.com India
Pulse Biosciences (NASDAQ:PLSE) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Pulse Biosciences (PLSE) Is Up 14.8% After Refocusing On nPulse AFib Catheter PlatformHas The Bull Case Changed? - simplywall.st
Pulse Biosciences shifts focus to cardiac catheter program By Investing.com - Investing.com South Africa
Pulse Biosciences Announces Organizational Realignment to Accelerate Cardiac Catheter Program After Exceptional AFib Clinical Results - Minichart
Pulse Biosciences Realigns Strategy Around nPulse AFib Platform - TipRanks
Pulse Biosciences (PLSE) realigns strategy around nPulse AFib catheter program - Stock Titan
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data - BioSpace
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program - marketscreener.com
Pulse Biosciences (PLSE) Prioritizes nPulse Cardiac Catheter Dev - GuruFocus
Pulse Biosciences shifts focus to cardiac catheter program - Investing.com
Is Pulse Biosciences’ (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy? - Yahoo Finance
A Look At Pulse Biosciences (PLSE) Valuation As Thyroid Cancer Feasibility Study Begins - Yahoo Finance
Pulse Biosciences enrolls first patients in thyroid cancer study - Investing.com Nigeria
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And DCF Estimate Gap - simplywall.st
Responsive Playbooks and the PLSE Inflection - Stock Traders Daily
A Look At Pulse Biosciences (PLSE) Valuation After Recent Share Price Swings - Sahm
Pulse Biosciences enrolls first patients in thyroid cancer study By Investing.com - Investing.com Canada
Pulse Biosciences Launches Thyroid Cancer Feasibility Study - TipRanks
Pulse Biosciences, Inc. Announces First Enrollments in Feasibilit - The National Law Review
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology - The Joplin Globe
Pulse Biosciences (NASDAQ:PLSE) Trading 8% HigherWhat's Next? - MarketBeat
Breakout Move: Can Pulse Biosciences Inc continue delivering strong returnsMarket Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Durable Thyroid Nodule Ablation Data Could Be A Game Changer For Pulse Biosciences (PLSE) - Sahm
Pulse Biosciences (PLSE) Reports Promising Long-Term Outcomes fo - GuruFocus
Pulse Biosciences Earnings Call: Data Strength Vs. Cash Burn - TipRanks
Pulse Biosciences Announces Long-Term Clinical Data for nPulse Vybrance Percutaneous Electrode System in Benign Thyroid Nodule Ablation 71314 - Minichart
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation - Investing News Network
Pulse Biosciences Reports Durable Thyroid Nodule Ablation Results - TipRanks
2.92%
자본화:
|
볼륨(24시간):